Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited ...Middle East

PR Newswire - News
Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited
STOCKHOLM, May 20, 2022 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment in...

Hence then, the article about lipidor updates on phase iii study of akp02 in treatment of psoriasis half of patients now recruited was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News